Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Recruiting 1No longer available 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 1Meningeal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 28Radiosurgery 19Radiotherapy 17Bevacizumab 12Magnetic Resonance Spectroscopy 9Radiation 6Erlotinib Hydrochloride 6Carboplatin 6Topotecan 5Nivolumab 5Mental Status and Dementia Tests 5Irinotecan 5Capecitabine 5pembrolizumab 4dabrafenib 4Trastuzumab 4Sunitinib 4Pemetrexed 4Ipilimumab 4Filgrastim 4Cyclophosphamide 4Aminolevulinic Acid 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4cabozantinib 3Vorinostat 3TPI-287 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Methylphenidate 3Lomustine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Brain Neoplasms × tucatinib × Clear all
NCT05553522 2025-12-31

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Baptist Health South Florida

Phase 1 Terminated
1 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡